Best Options Strategy for RARE
Looking for the best options strategy for Ultragenyx Pharmaceutical Inc. (RARE)? There is no single answer — the right play depends on your outlook, your risk tolerance and current implied volatility. Below, our free engine shows the highest-scoring defined-risk strategy on the live RARE option chain right now, and a simple map from your view on RARE to the strategy that fits it. Model any of them in the calculator before you trade.
About RARE
Ultragenyx Pharmaceutical Inc. (RARE) is a major company in Biotechnology. Options traders on RARE tend to watch , since these can drive large moves in the share price.
About Ultragenyx Pharmaceutical Inc.
# About Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical is a biopharmaceutical company developing and commercializing treatments for rare and ultra-rare genetic diseases. The company operates across North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific region. Its marketed products include Crysvita, a monoclonal antibody used for X-linked hypophosphatemia and tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for mucopolysaccharidosis VII; Dojolvi for long-chain fatty acid oxidation disorders; and Evkeeza for homozygous familial hypercholesterolemia. Beyond these approved therapies, Ultragenyx maintains a pipeline of candidates in advanced development, including several gene therapy programs in Phase 3 trials targeting conditions like osteogenesis imperfecta, Sanfilippo syndrome, glycogen storage disease, and ornithine transcarbamylase deficiency, plus an antisense therapy for Angelman syndrome.
The company generates revenue from its approved product sales while advancing its pipeline toward commercialization. Its business model relies on partnerships and licensing agreements with organizations including Kyowa Kirin,…
Today's top-scoring strategy for RARE
Our engine ranks defined-risk strategies on the live RARE chain by probability of profit and risk/reward, then surfaces the best-scoring one. It is an educational illustration, not advice.
| Action | Qty | Type | Strike | Premium |
|---|---|---|---|---|
| Buy | 1× | PUT | $20 | $0.11 |
| Sell | 1× | PUT | $30 | $0.50 |
| Sell | 1× | CALL | $32.5 | $1.63 |
| Buy | 1× | CALL | $37.5 | $0.50 |
Simulation
Forward simulation of 6,000 lognormal price paths to expiration — not a historical backtest.
Live scan from 2026-07-02 · quotes delayed ~15 minutes
Implied volatility
RARE is currently trading with high implied volatility, which makes its options expensive — and attractive to sell. On the options we scanned that was around 60% implied volatility, and higher implied volatility means richer premiums and wider expected moves.
Options on RARE currently price in about 60% implied volatility, versus roughly 57% the stock has actually realised over the past month. The two are roughly in line, so neither buying nor selling premium has a clear volatility edge here.
Off that volatility, the options market is pricing a move of about ±$3.87 (±12%) in RARE by 2026-07-17 — a range of roughly $28.83 to $36.57. Strikes inside that band hold most of the premium and see most of the action.
Across strikes, downside puts on RARE trade at a higher implied volatility than upside calls — the market is paying up for crash protection. That skew favours selling put spreads or buying calls over symmetric trades.
Liquidity and tradeability
RARE options are thinly traded, with wide bid-ask spreads around 46.2% near the money that eat into any edge — favour simple single-leg or tight defined-risk trades, and always use limit orders.
Earnings & IV crush
RARE's next earnings report is due around August 4, 2026. Options that expire after it price in a binary move, so their implied volatility is elevated and usually collapses right after the announcement — an "IV crush". If your expiration falls before this date, the trade sidesteps the event.
Key figures
- Market cap
- $3.3B
- Beta (vs market)
- 0.38
- 52-week range
- $18.29–$42.37 (60% up the range)
- Short interest
- 15.0% of float · 9.1 days to cover
With 15.0% of RARE's float sold short, squeeze and gap risk are elevated — one reason its options can stay expensive.
Other strong setups for RARE
If your view on RARE differs, these also scored well in the latest scan:
How to choose an options strategy for RARE
Start with your outlook on RARE, then match it to a defined-risk structure. Here are the most common choices and when each makes sense:
Bullish
Buy a call for leverage with capped risk, or a bull call spread to lower the cost and breakeven when you have a target price.
Long Call → Bull Call Spread →Bearish
Buy a put to profit from a decline with defined risk, or a bear put spread to cheapen the trade when you expect a measured move down.
Long Put → Bear Put Spread →Neutral
Sell an iron condor to collect premium while RARE stays between two strikes, or write a covered call against shares you already own.
Iron Condor → Covered Call →How we pick the best strategy
For each ticker we pull the live option chain, build every supported strategy around the at-the-money strikes, and score them on probability of profit, risk/reward and capital efficiency — favouring defined-risk structures where the maximum loss is known up front. Methodology →
Open RARE in the free calculator →
Frequently asked questions
What is the best options strategy for RARE?
It depends on your outlook. Bullish traders often use a long call or bull call spread on RARE; bearish traders a long put or bear put spread; neutral traders an iron condor or covered call. Our live scan above shows the current highest-scoring defined-risk play.
Are RARE options liquid enough to trade?
Ultragenyx Pharmaceutical Inc. (RARE) is among the most actively-traded US options, which usually means tight bid/ask spreads and plenty of strikes and expirations — though you should always check the open interest and spread on the exact contract.
How much money do I need to trade RARE options?
Buying a single RARE call or put can cost as little as the premium (often one to a few hundred dollars), while income strategies like a cash-secured put need enough capital to buy 100 shares if assigned.
Is this financial advice?
No. Everything here is educational and uses delayed, third-party data. It is not a recommendation to trade RARE or any security. Do your own research.
What does Ultragenyx Pharmaceutical Inc. do?
Ultragenyx Pharmaceutical Inc. (RARE) operates in the Biotechnology industry. The "About Ultragenyx Pharmaceutical Inc." section above gives a fuller picture of what the company does and how it earns money.
Does Ultragenyx Pharmaceutical Inc. pay a dividend?
Ultragenyx Pharmaceutical Inc. does not currently pay a dividend, so there is no ex-dividend assignment risk to plan around for options strategies.
When does Ultragenyx Pharmaceutical Inc. next report earnings?
Ultragenyx Pharmaceutical Inc.'s next earnings are expected around August 4, 2026. Implied volatility usually climbs into the report and drops sharply afterwards (IV crush) — important for any options position held over the date.
Tickers related to RARE
Comparing RARE with similar names can help you choose the best options strategy:
Company information
- Headquarters
- 60 Leveroni Court, Novato, CA, 94949, United States
- Industry
- Biotechnology
- Employees
- 1,371
- CEO
- Dr. Emil D. Kakkis M.D., Ph.D.
- Phone
- 415 483 8800
- Website
- www.ultragenyx.com
Best Options Strategy by Ticker →
Educational use only. Quotes are delayed ~15 minutes and nothing here is financial advice. Options trading involves substantial risk of loss. Privacy · Terms.